Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07582354

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity

This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.

The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Myeloma Multiple Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS AOU Policlinico Sant'Orsola

Bologna, Bo, 40138, Italy

Location status: Recruiting

Location contact

Carolina Terragna, MD

CONTACT

[email protected]

0512143680

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18+
  • Signed CI for study partecipation and personal data processing.
  • Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Response assessment (according to IMWG criteria) and / or disease progression (PD)

    Time frame: 12 months after the start of therapy, in pre-neoplastic groups , only PD will be considered

Secondary outcomes

  1. Response to treatment <VGPR (according to IMWG criteria) and/or disease progression (PD)

    Time frame: From baseline to disease progression (PD), assessed up to 24 months.

  2. Presence and/or absence of "secondary" tumor clone(s)

    Time frame: From baseline to disease progression (PD), assessed up to 24 months.

  3. Presence and/or absence of differences between baseline characteristics and progression features

    Time frame: From baseline to disease progression (PD), assessed up to 24 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Carolina Terragna, MD

CONTACT

[email protected]

0512143831

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2032
First posted
May 12, 2026
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.